KID syndrome

KID syndrome (Keratitis-Ichthyosis-Deafness syndrome), also known as keratitis-ichthyosis-deafness syndrome or Senter syndrome, is a rare congenital disorder characterized by the triad of vascularizing keratitis (inflammation of the cornea with abnormal blood vessel growth), ichthyosis-like skin changes, and sensorineural hearing loss. The condition is caused by mutations in the GJB2 gene, which encodes connexin 26, a gap junction protein critical for cell-to-cell communication in the skin, inner ear, and cornea. Most cases arise from de novo (new) dominant mutations, particularly the recurrent p.Asp50Asn missense variant. The skin manifestations include widespread erythrokeratoderma (red, thickened skin), well-demarcated hyperkeratotic plaques, and a distinctive stippled or grainy appearance of the skin. Palmoplantar keratoderma (thickened skin on palms and soles) is common. The hair and nails may also be affected, with sparse hair or alopecia and dystrophic nails. The progressive vascularizing keratitis can lead to significant visual impairment or blindness if untreated. Sensorineural hearing loss is typically profound and congenital. Patients are at increased risk for mucocutaneous infections, particularly chronic mucocutaneous candidiasis, and there is a notably elevated risk of developing squamous cell carcinoma of the skin, which requires lifelong surveillance. There is no cure for KID syndrome. Management is multidisciplinary and supportive, involving dermatologic care with emollients and keratolytics for skin manifestations, ophthalmologic monitoring and treatment (including corneal transplantation in severe cases), hearing aids or cochlear implants for hearing loss, and vigilant screening for skin cancers. Antifungal therapy is used for recurrent candidal infections. Early intervention for hearing loss is critical for speech and language development.

Common questions about KID syndrome